Pengcheng Shi

Guangzhou, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 51 publications

Enhanced prognosis of acute myeloid leukaemia patients with dmCEBPAbZIP -inf mutations: Insights from a multicentre Chinese cohort study.

Enhanced prognosis of acute myeloid leukaemia patients with dmCEBPAbZIP -inf mutations: Insights from a multicentre Chinese cohort study.

Journal: British journal of haematology

Published: May 22, 2026

Autologous transplant versus matched sibling donor transplant in intermediate-risk AML in CR1 with no detectable MRD: a biological assignment comparative study.

Autologous transplant versus matched sibling donor transplant in intermediate-risk AML in CR1 with no detectable MRD: a biological assignment comparative study.

Journal: Experimental hematology & oncology

Published: March 25, 2026

Potential therapeutic GSK-3β inhibitor 9-ING-41 is active in combination with venetoclax in double-hit lymphoma (DHL).

Potential therapeutic GSK-3β inhibitor 9-ING-41 is active in combination with venetoclax in double-hit lymphoma (DHL).

Journal: Cancer biology & therapy

Published: November 12, 2025

Single-cell profiling reveals reprogrammed hierarchy and disrupted immune-stromal ecosystem in TP53-mutated AML.

Single-cell profiling reveals reprogrammed hierarchy and disrupted immune-stromal ecosystem in TP53-mutated AML.

Journal: Experimental hematology & oncology

Published: October 14, 2025

Decitabine combined with reduced-intensity conditioning for older patients with acute myeloid leukemia in composite complete remission undergoing allogeneic hematopoietic stem cell transplantation: a multicenter, single-arm, phase 2 trial.

Decitabine combined with reduced-intensity conditioning for older patients with acute myeloid leukemia in composite complete remission undergoing allogeneic hematopoietic stem cell transplantation: a multicenter, single-arm, phase 2 trial.

Journal: The Lancet regional health. Western Pacific

Published: February 26, 2025

High-dose cytarabine with idarubicin consolidation for acute myeloid leukemia in first complete remission: a randomized controlled trial.

High-dose cytarabine with idarubicin consolidation for acute myeloid leukemia in first complete remission: a randomized controlled trial.

Journal: Leukemia

Published: January 20, 2025

Venetoclax added to CLAG regimen might improve the outcome of patients with relapsed/refractory acute myeloid leukemia.

Venetoclax added to CLAG regimen might improve the outcome of patients with relapsed/refractory acute myeloid leukemia.

Journal: Therapeutic advances in hematology

Published: August 12, 2024

Homoharringtonine may help improve the outcomes of venetoclax and azacitidine in AML1-ETO positive acute myeloid leukemia.

Homoharringtonine may help improve the outcomes of venetoclax and azacitidine in AML1-ETO positive acute myeloid leukemia.

Journal: Journal of cancer research and clinical oncology

Published: May 27, 2024

Homoharringtonine Added to Venetoclax and Azacitidine Improves Outcome and Mitigates Genetic Impact in Relapsed/Refractory AML: A Multicenter Cohort Study.

Homoharringtonine Added to Venetoclax and Azacitidine Improves Outcome and Mitigates Genetic Impact in Relapsed/Refractory AML: A Multicenter Cohort Study.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: April 30, 2024

Dynamic evolution of bone marrow adipocyte in B cell acute lymphoblastic leukemia: insights from diagnosis to post-chemotherapy.

Dynamic evolution of bone marrow adipocyte in B cell acute lymphoblastic leukemia: insights from diagnosis to post-chemotherapy.

Journal: Cancer biology & therapy

Published: March 11, 2024

Changing epidemiology, microbiology and mortality of bloodstream infections in patients with haematological malignancies before and during SARS-CoV-2 pandemic: a retrospective cohort study.

Changing epidemiology, microbiology and mortality of bloodstream infections in patients with haematological malignancies before and during SARS-CoV-2 pandemic: a retrospective cohort study.

Journal: BMJ open

Published: December 30, 2023

Sorafenib plus triplet therapy with venetoclax, azacitidine and homoharringtonine for refractory/relapsed acute myeloid leukemia with FLT3-ITD: A multicenter phase 2 study.

Sorafenib plus triplet therapy with venetoclax, azacitidine and homoharringtonine for refractory/relapsed acute myeloid leukemia with FLT3-ITD: A multicenter phase 2 study.

Journal: Journal of internal medicine

Published: October 29, 2023

Showing 1-12 of 51

Last Updated: 09/26/2026